Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

@article{Johnston2001RandomisedTO,
  title={Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack},
  author={Dennis Johnston},
  journal={The Lancet},
  year={2001},
  volume={358},
  pages={1033-1041}
}
BACKGROUND Blood pressure is a determinant of the risk of stroke among both hypertensive and non-hypertensive individuals with cerebrovascular disease. However, there is uncertainty about the efficacy and safety of blood-pressure-lowering treatments for many such patients. The perindopril protection against recurrent stroke study (PROGRESS) was designed to determine the effects of a blood-pressure-lowering regimen in hypertensive and non-hypertensive patients with a history of stroke or… Expand

Paper Mentions

Interventional Clinical Trial
PRECIOUS Study aims to evaluate the efficacy and safety of therapy with fixed-dose combination (FDC) of perindopril/amlodipine (Amlessa®) and FDC of perindopril/indapamide… Expand
ConditionsHypertension
InterventionDrug
Interventional Clinical Trial
The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke… Expand
ConditionsAcute Stroke, Cerebrovascular Accident
InterventionDrug
Effects of a perindopril-based blood-pressure-lowering regimen in patients with previous stroke or transient ischaemic attack (progress). How do the results affect practice in Pakistan?
TLDR
The aim of this particular study was to determine the effects of a flexible blood pressure lowering regimen on the risk of stroke recurrence and other major vascular events in patients who had a history of stroke or Transient ischaemic attack. Expand
Efficacy and Tolerability of Fixed-Dose Combination Perindopril/Indapamide in Hypertensive Patients with a History of Stroke or Transient Ischemic Attack: PICASSO Trial
TLDR
This study suggests that fixed combination perindopril 10 mg/indapamide 2.5 mg is an effective and well-tolerated treatment for patients with a history of stroke or transient ischemic attack, and decreases in SBP/DBP were statistically significant in patients with all grades of hypertension. Expand
Secondary Prevention of Coronary Disease with ACE Inhibition-does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?
TLDR
The treatment benefit in EUROPA cannot be fully explained by baseline BP or BP reduction with perindopril, and other mechanisms including direct anti-atherosclerotic effects of ACE inhibition may play a role. Expand
Control of blood pressure after stroke.
Acornerstone of primary stroke prevention is built on treating “hypertension” in asymptomatic subjects who are usually at low or medium vascular risk, dogma based on the results of numerousExpand
Stroke secondary prevention and blood pressure reduction: an observational study of the use of PROGRESS therapy
TLDR
This study shows that mention of PROGRESS therapy in the discharge summary must be improved as it is associated with a higher use of these anti‐hypertensive agents 1’year after stroke/TIA. Expand
Cerebrovascular protection and antihypertensive therapy.
TLDR
The association between blood pressure and stroke is reviewed and data from randomized controlled trials involving diverse therapies, especially those regarding the renin-angiotensin system are analysed, to determine specific effects of drug classes on cardiovascular risk. Expand
Perindopril: the evidence of its therapeutic impact in hypertension
TLDR
There is strong evidence supporting the use of perindopril-based therapy for the treatment of hypertension and reduction in the risk of cardiovascular disease, stroke, and death in a wide range of patients with stable coronary artery disease or hypertension. Expand
Blood Pressure–Lowering for Secondary Prevention of Stroke: ACE Inhibition Is the Key
Angiotensin-converting enzyme (ACE) inhibitors undoubtedly represent one of the major advances in cardiovascular therapeutics over the past 20 years. Having been originally derived from the venom ofExpand
Prevention of stroke: Antihypertensives, cholesterol-lowering drugs, antithrombotics, anticoagulation, carotid surgery, and stenting
TLDR
Antihypertensive drugs are very effective in secondary stroke prevention and should be treated with optimal medical management, which includes antiplatelet therapy and high-dose statins (if deemed appropriate). Expand
Comparison of Hypertension Management After Stroke and Myocardial Infarction: Results From ECLAT1—A French Nationwide Study
TLDR
The results highlight the need for information provided to practitioners to recall the importance of hypertension control in this situation and to increase the use of combination therapy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
PROGRESS - Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Progress Management Committee.
  • Medicine
  • Journal of hypertension
  • 1999
TLDR
The successful completion of recruitment and current indicators of statistical power suggest that the Perindopril Protection Against Recurrent Stroke Study should achieve its primary aim on schedule. Expand
Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS
  • L. Hansson
  • Medicine
  • Journal of hypertension. Supplement : official journal of the International Society of Hypertension
  • 1996
TLDR
The primary objective of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) is to determine the effects of blood pressure reduction on stroke risk in patients with a history of cerebrovascular disease. Expand
Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations*
This review of the effectiveness of treatment for acute stroke and methods of secondary prevention shows that the highest priority for providers of a stroke service must be to establish a stroke unitExpand
Blood pressure lowering for the secondary prevention of myocardial infarction and stroke.
TLDR
Questions about the safety of BP reduction for patients with preexisting cardiovascular disease have been raised following observations of J- and U-shaped associations between BP levels and the risks of recurrent myocardial infarction and stroke. Expand
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials
TLDR
Strong evidence of benefits of ACE inhibitors and calcium antagonists is provided by the overviews of placebo-controlled trials, and data from continuing trials of blood-pressure-lowering drugs will substantially increase the evidence available about any real differences that might exist between regimens. Expand
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
TLDR
Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure. Expand
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
TLDR
This study shows that long-term treatment with simvastatin is safe and improves survival in CHD patients, and a 37% reduction in the risk of undergoing myocardial revascularisation procedures. Expand
Blood pressure and risk of stroke in patients with cerebrovascular disease
TLDR
There is widespread clinical uncertainty about lowering blood pressure in patients with ischaemic cerebrovascular disease, and concern has arisen partly from reports of a J shaped association between blood pressure and recurrent stroke in these patients. Expand
Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts
TLDR
The associations of blood cholesterol and diastolic blood pressure with subsequent stroke rates were investigated by review of 45 prospective observational cohorts involving 450,000 individuals with 5-30 years of follow-up, finding that the effects of therapeutic blood pressure reductions should be assessed separately in middle age and in old age. Expand
Blood pressure control and recurrence of hypertensive brain hemorrhage.
TLDR
Higher diastolic BP was related to an increased rate of rebleeding and may be regarded as a factor predictive of the recurrence of HBH. Expand
...
1
2
...